Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion
October 01, 2024 08:30 ET
|
Evoke Pharma, Inc.
Nantahala to nominate 2 board seats Portion of the proceeds received from warrants executed at $8.16/share SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc....
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments
September 19, 2024 14:20 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results
August 13, 2024 08:00 ET
|
Evoke Pharma, Inc.
GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million Achieved record-high prescription fills...
Evoke Pharma, Inc. Supports Gastroparesis Awareness Month
August 08, 2024 08:30 ET
|
Evoke Pharma, Inc.
Collaborating with advocacy groups to amplify gastroparesis awareness for millions of patients worldwide Call for action to improve health and access for patients SOLANA BEACH, Calif., Aug....
Evoke Pharma, Inc. Announces Reverse Stock Split
July 30, 2024 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI
June 17, 2024 08:30 ET
|
Evoke Pharma, Inc.
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA...
Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference
May 16, 2024 16:02 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports First Quarter 2024 Financial Results
May 14, 2024 16:15 ET
|
Evoke Pharma, Inc.
114% year-over-year increase in net product sales70% prescriber growth in Q1 2024 compared to Q4 2023Growing sales metrics reaffirms company’s $14M net revenue guidance for 2024 SOLANA BEACH, Calif.,...
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
March 21, 2024 16:15 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024 16:05 ET
|
Evoke Pharma, Inc.
Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022 Company projects $14M in net revenue for 2024 SOLANA BEACH, Calif., March 14, 2024 ...